Sunovion Pharmaceuticals Files Two Supplemental New Drug Applications Seeking Approval for the use of Latuda® …

Sunovion Pharmaceuticals Inc. today announced that it has submitted two supplemental New Drug Applications to the U.S. Food and Drug Administration seeking approval for the use of LATUDA as 1) monotherapy and 2) adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder .

Leave a reply